Apparent interference with extracorporeal membrane oxygenation by liposomal amphotericin B in a patient with disseminated blastomycosis receiving continuous renal replacement therapy.

PURPOSE We describe the use of liposomal amphotericin B and amphotericin B deoxycholate in a critically ill patient with pulmonary blastomycosis receiving both venovenous extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). SUMMARY A 50-year-old African American man presented for dyspnea and cough and was noted to have blastomycosis on bronchoscopy. He developed respiratory failure and acute kidney injury, requiring mechanical ventilation, ECMO, and CRRT. After 4 days of liposomal amphotericin, the transmembrane pressure gradient on the membrane oxygenator increased dramatically without visualization of a clot, requiring a circuit exchange. A trough amphotericin B level taken the day before the exchange was undetectable for amphotericin B. After the circuit exchange, the patient was switched to amphotericin B deoxycholate. A subsequent trough level was 3.8 μg/mL. The patient improved and was able to be decannulated. However, he did require tracheostomy and long-term hemodialysis. CONCLUSION In our case we believe that liposomal amphotericin B was significantly removed by ECMO and was responsible for the failure of the ECMO circuit. We would suggest amphotericin B deoxycholate be used in such patients preferentially and that serum levels of the drug be assessed when possible.

[1]  A. Sieg,et al.  Evaluation of Altered Drug Pharmacokinetics in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation , 2017, Pharmacotherapy.

[2]  John F. Fraser,et al.  Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models , 2015, Critical Care.

[3]  D. Stevens,et al.  39 – Drugs Active against Fungi, Pneumocystis, and Microsporidia , 2015 .

[4]  O. Corrigan,et al.  Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration. , 2013, International journal of antimicrobial agents.

[5]  R. Hamill.  Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity , 2013, Drugs.

[6]  J. Roberts,et al.  Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. , 2011, Critical care clinics.

[7]  Ross Freebairn,et al.  Principles of antibacterial dosing in continuous renal replacement therapy , 2009, Critical care medicine.

[8]  E. Trepman,et al.  Clinical Characteristics and Outcomes in Patients with Pulmonary Blastomycosis , 2009, Mycopathologia.

[9]  M. Threlkeld,et al.  Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Bouadma,et al.  Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation , 2008, Intensive Care Medicine.

[11]  C. Wiedermann,et al.  Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. , 2004, International journal of antimicrobial agents.

[12]  W. Wilmanns,et al.  Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients , 1997, Antimicrobial agents and chemotherapy.